Hernandez, Rosmely
Toomer, Kevin H.
Põder, Janika
Santos Savio, Alicia
Hsiung, Sunnie
Malek, Thomas R. http://orcid.org/0000-0001-7174-0434
Funding for this research was provided by:
National Institutes of Health (R21CA195334)
Sylvester Comprehensive Cancer Center
Article History
Received: 1 June 2020
Accepted: 9 September 2020
First Online: 10 October 2020
Compliance with ethical standards
:
: The University of Miami, T.R.M. and R.H. have patents pending on IL-2/CD25 fusion proteins (Wo2016022671A1;T.R.M) and their use (PCT/US20/13152; T.R.M., R.H) that have been licensed exclusively to Bristol Myers Squibb, and some research on IL-2/CD25 fusion proteins has been supported in part by a collaboration and sponsored research and licensing agreement with Bristol Myers Squibb. The other authors have no financial conflicts of interest.
: Animal studies were approved by the Institutional Animal Care and Use Committee at the University of Miami (Protocol 18-147).
: Not applicable.
: Not applicable.